Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

475837 MIF Antagonist, ISO-1 - CAS 478336-92-4 - Calbiochem

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
478336-92-4C₁₂H₁₃NO₄

Products

Catalogue NumberPackaging Qty/Pack
475837-5MG Plastic ampoule 5 mg
Description
OverviewA cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF tautomerase activity by binding to its catalytic active site (IC50 = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes, and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model. Also available as a 50 mM solution in DMSO (Cat. No. 505225).
Catalogue Number475837
Brand Family Calbiochem®
Synonyms(S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid, methyl ester, Macrophage Migration Inhibitory Factor Antagonist, ISO-1
References
ReferencesCvetkovic, I., et al. 2005. Endocrinology, 146, 2942.
Lubetsky, J.B., et al. 2002. J. Biol. Chem. 277, 24976.
Product Information
CAS number478336-92-4
ATP CompetitiveN
FormLight yellow solid
Hill FormulaC₁₂H₁₃NO₄
Chemical formulaC₁₂H₁₃NO₄
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationMIF Antagonist, ISO-1, CAS 478336-92-4, is a cell-permeable inhibitor of MIF tautomerase (IC50 = 7 µM for D-dopachrome tautomerase). Suppresses the production of TNFα, PGE2 & COX-2 in monocytes.
Biological Information
Primary TargetMIF tautomerize
Primary Target IC<sub>50</sub>7 µM for D-dopachrome tautomerase
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
475837-5MG 04055977184969

Documentation

MIF Antagonist, ISO-1 - CAS 478336-92-4 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

MIF Antagonist, ISO-1 - CAS 478336-92-4 - Calbiochem Certificates of Analysis

TitleLot Number
475837

References

Reference overview
Cvetkovic, I., et al. 2005. Endocrinology, 146, 2942.
Lubetsky, J.B., et al. 2002. J. Biol. Chem. 277, 24976.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-July-2014 JSW
Synonyms(S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid, methyl ester, Macrophage Migration Inhibitory Factor Antagonist, ISO-1
DescriptionA cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC50 = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model.
FormLight yellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number478336-92-4
Chemical formulaC₁₂H₁₃NO₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (10 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesCvetkovic, I., et al. 2005. Endocrinology, 146, 2942.
Lubetsky, J.B., et al. 2002. J. Biol. Chem. 277, 24976.